```html

White‑Clot Stroke (Cerebral Venous Thrombosis)

Overview

White‑clot stroke is a lay‑term for cerebral venous thrombosis (CVT), a rare type of stroke caused by a blood clot (thrombus) forming in the brain’s venous sinuses or cortical veins. Unlike the more common “red‑clot” arterial strokes that block oxygen‑rich blood flow, CVT blocks the brain’s drainage system, leading to increased intracranial pressure, venous congestion, and sometimes hemorrhage.

• Who it affects: Adults of any age, but most cases occur in people aged 20‑50 years.
• Sex distribution: Women are 2‑3 times more likely to develop CVT, largely because of hormonal risk factors (pregnancy, oral contraceptives).
• Prevalence: CVT accounts for 0.5–1% of all strokes worldwide, translating to roughly 5–10 cases per million people each year. In some high‑risk groups (e.g., postpartum women) the incidence rises to 15–20 per 100,000 pregnancies.<sup>1</sup>

Symptoms

Because CVT can involve many different venous structures, symptoms are often varied and may develop gradually over days to weeks. The most common presenting features are:

• Headache: Persistent, worsening, often described as “worst headache of my life” or a dull, pressure‑like pain that may be worse when lying down.
• Focal neurological deficits: Weakness or numbness in one arm or leg, facial droop, or difficulty speaking (aphasia).
• Seizures: Occur in 30–40% of patients; can be generalized or focal.
• Vision changes: Blurred vision or transient visual loss due to papilledema from raised intracranial pressure.
• Vomiting & nausea: Often non‑bilious and associated with headache.
• Altered consciousness: Ranges from mild confusion to coma in severe cases.
• Neck stiffness: May mimic meningitis when there is subarachnoid hemorrhage.
• Auditory or facial sensory disturbances: Tinnitus, facial numbness, or a sensation of “swelling” in the ear.

Symptoms can be isolated (e.g., only headache) or combined. In pregnant or postpartum women, a new‑onset severe headache or seizure should raise immediate suspicion for CVT.

Causes and Risk Factors

CVT is essentially a hypercoagulable state plus anatomical or physiological conditions that slow venous flow. Major contributors include:

1. Hormonal factors

• Oral contraceptive pills (particularly those containing estrogen)
• Hormone replacement therapy
• Pregnancy and the postpartum period (especially the first 6 weeks)

2. Inherited or acquired thrombophilias

• Factor V Leiden mutation
• Prothrombin G20210A mutation
• Protein C, Protein S, or Antithrombin deficiency
• Elevated homocysteine (hyperhomocysteinemia)
• Antiphospholipid antibody syndrome

3. Systemic diseases

• Malignancy (especially brain tumors or metastatic disease)
• Inflammatory bowel disease (Crohn’s, ulcerative colitis)
• Sickle cell disease
• Systemic infections (e.g., meningitis, sinusitis) that spread to the dural sinuses
• Nephrotic syndrome

4. Local factors

• Head trauma or skull base fractures
• Neurosurgical procedures or lumbar puncture
• Otitis media, mastoiditis, or sinus infections that extend to the cavernous sinus

5. Lifestyle & other contributors

• Obesity
• Smoking
• Prolonged immobilization (e.g., long flights, bed rest)

Often, more than one risk factor is present; for example, a postpartum woman on combined‑oral contraceptives who also carries Factor V Leiden has a significantly higher risk.

Diagnosis

A high index of suspicion is essential, especially in young women with atypical headaches or seizures. The diagnostic pathway generally follows these steps:

1. Clinical evaluation

• Detailed history (onset, progression, risk factors)
• Neurological exam to localize deficits

2. Imaging studies

• CT venography (CTV): Fast, widely available; demonstrates filling defects in the venous sinuses.
• Magnetic resonance venography (MRV): Gold standard for visualizing thrombus and assessing brain parenchyma; can differentiate acute vs. chronic clot.
• Non‑contrast CT: May show hyperdense sinus (“dense triangle sign”) or secondary hemorrhage, but is less sensitive.
• Conventional digital subtraction angiography (DSA): Reserved for ambiguous cases or when endovascular therapy is contemplated.

3. Laboratory work‑up

• Complete blood count, coagulation profile (PT, aPTT, INR)
• Screen for thrombophilia (once the acute phase is over): Factor V Leiden, prothrombin mutation, antiphospholipid antibodies, protein C/S, antithrombin.
• Serum inflammatory markers (CRP, ESR) if infection or autoimmune disease is suspected.

4. Ancillary tests

• Electroencephalogram (EEG) if seizures are present.
• Lumbar puncture only if infection or subarachnoid hemorrhage is in the differential; be cautious of raised intracranial pressure.

Treatment Options

Timely treatment dramatically reduces morbidity and mortality. Management consists of acute anticoagulation, treatment of underlying causes, and symptomatic care.

1. Anticoagulation

• Initial therapy: Low‑molecular‑weight heparin (LMWH) (e.g., enoxaparin 1 mg/kg subcutaneously q12h) or unfractionated heparin infusion when rapid reversal may be needed.
• Transition to oral anticoagulants: Warfarin (target INR 2.0–3.0) for 3–12 months, or a direct oral anticoagulant (DOAC) such as apixaban or rivaroxaban (evidence supports DOACs as safe alternatives in CVT; see NEJM 2020).
• Duration depends on provoking factor: 3 months for transient risk (e.g., postpartum), 6–12 months for thrombophilia, indefinite if permanent risk persists.

2. Management of Intracranial Hypertension

• Head elevation, analgesics, and anti‑emetics.
• Osmotic agents (mannitol) or hypertonic saline in severe cases.
• Therapeutic lumbar puncture can be considered if papilledema persists and imaging excludes mass effect.

3. Seizure Control

• Antiepileptic drugs (AEDs) such as levetiracetam or lamotrigine are started after a first seizure; many clinicians continue AEDs for 6–12 months.

4. Endovascular Therapy (rare)

• Mechanical thrombectomy or local thrombolysis may be employed in patients who deteriorate despite adequate anticoagulation and have large clot burden, especially in the superior sagittal sinus.
• Evidence remains limited; performed in specialized centers.

5. Treating Underlying Causes

• Infection: appropriate antibiotics.
• Autoimmune disease: immunosuppressive therapy.
• Pregnancy‑related CVT: anticoagulation is safe; delivery planning with obstetrics is essential.

Living with White‑Clot Stroke (Cerebral Venous Thrombosis)

Survivors often lead active lives, but ongoing care helps prevent recurrence and manage lingering effects.

Medication adherence

• Take anticoagulant exactly as prescribed; set daily reminders.
• Know how to monitor warfarin (INR checks) or recognize signs of DOAC overdose (unusual bruising, bleeding).

Follow‑up imaging

• Repeat MRV or CTV at 3–6 months to document recanalization.
• Long‑term imaging may be needed if symptoms persist.

Rehabilitation

• Physical therapy for weakness or gait instability.
• Occupational therapy for fine‑motor deficits.
• Speech‑language therapy if aphasia or dysphagia occurred.

Lifestyle modifications

• Maintain a healthy weight (BMI < 25 kg/m²).
• Stay physically active—aim for at least 150 min of moderate aerobic activity per week.
• Avoid smoking and limit alcohol to ≤ 2 drinks per day for men, ≤ 1 for women.
• Stay hydrated, especially during long travel or immobilization.

Psychosocial support

• Depression and anxiety are common after stroke; counseling or support groups can be valuable.
• Consider a neuropsychology evaluation if memory or executive function problems linger.

Prevention

Because many risk factors are modifiable, targeted strategies can markedly lower recurrence risk.

• Contraception: Women with thrombophilia or prior CVT should discuss non‑estrogen options (e.g., progestin‑only pills, IUDs) with their provider.
• Pregnancy care: High‑risk women receive prophylactic LMWH during pregnancy and the postpartum period.
• Thrombophilia screening: Family history of clotting disorders warrants testing; positive results guide long‑term anticoagulation decisions.
• Infection control: Prompt treatment of sinusitis, mastoiditis, or dental infections reduces spread to cerebral veins.
• Hospital protocols: Early mobilization after surgery, compression stockings for immobile patients, and prophylactic LMWH when indicated.
• Medication review: Avoid combining estrogen‑containing drugs with other pro‑thrombotic agents unless essential.

Complications

If untreated or inadequately managed, CVT can lead to serious short‑ and long‑term problems:

• Venous infarction: Brain tissue death due to congestion; may become hemorrhagic.
• Intracerebral hemorrhage: Up to 30% of patients develop bleed; worsens prognosis.
• Persistent neurological deficits: Weakness, sensory loss, or language impairment lasting months to years.
• Seizure disorder: Chronic epilepsy develops in 10–15% of patients.
• Chronic headache: Migraine‑like or tension‑type headaches can persist despite clot resolution.
• Vision loss: From papilledema or optic nerve damage.
• Mortality: Early mortality is 5–10% in high‑resource settings, higher in low‑resource areas.<sup>2</sup>

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. Cerebral Venous Thrombosis. Accessed May 2024.
2. World Health Organization. Stroke Fact Sheet. 2023.
3. American Heart Association. 2022 Guidelines for the Early Management of Acute Ischemic Stroke.
4. NIH National Institute of Neurological Disorders and Stroke. Cerebral Venous Thrombosis Fact Sheet. 2022.
5. Gosk, J. et al. “Direct oral anticoagulants for cerebral venous thrombosis: a systematic review.” Neurology, 2020.

```